Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...
Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic lymphocytic leukemia (CLL) has undergone a seismic shift, moving from the ...
The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted approaches. Highlights include: Continuous vs. fixed-duration therapy: A debate on ...
Richter transformation with CNS involvement in CLL patients results in poor prognosis and limited survival, with a median overall survival of 13 months. Treatment strategies for RT-CNS are often ...
Hosted on MSN
AbbVie Says Cancer Drug Failed To Prolong Survival In Late-Stage Study: Retail’s On The Fence
AbbVie (ABBV) said on Monday that its late-stage trial evaluating its drug Venetoclax in combination with Azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) ...
Hosted on MSN
A new all oral treatment for AML on the horizon for patients struggling to withstand chemo
A new all-oral treatment option may soon be available for some older adults with acute myeloid leukemia (AML) who are not able to tolerate intensive chemotherapy, according to Dr. Tiffany Tanaka, an ...
Sellas Life Sciences faces a high bar with its Phase 3 REGAL trial for GPS in AML second remission. REGAL’s ambitious hazard ratio target, open-label design, and heterogeneous control arm raise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results